{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:52:22Z","timestamp":1782337942229,"version":"3.54.5"},"reference-count":12,"publisher":"Impact Journals, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,2,23]]},"DOI":"10.18632\/oncotarget.6984","type":"journal-article","created":{"date-parts":[[2016,1,23]],"date-time":"2016-01-23T01:18:31Z","timestamp":1453511911000},"page":"9041-9045","source":"Crossref","is-referenced-by-count":6,"title":["Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy"],"prefix":"10.18632","volume":"7","author":[{"given":"Bryan","family":"Oronsky","sequence":"first","affiliation":[{"name":"EpicentRx, Inc., Mountain View, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Carter","sequence":"additional","affiliation":[{"name":"Walter Reed National Military Medical Center, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Scicinska","sequence":"additional","affiliation":[{"name":"EpicentRx, Inc., Mountain View, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Oronsky","sequence":"additional","affiliation":[{"name":"InterWest Partners, Menlo Park, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Oronsky","sequence":"additional","affiliation":[{"name":"CFLS, LLC, San Jose, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Lybeck","sequence":"additional","affiliation":[{"name":"EpicentRx, Inc., Mountain View, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Scicinski","sequence":"additional","affiliation":[{"name":"EpicentRx, Inc., Mountain View, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,1,22]]},"reference":[{"key":"1","volume-title":"Studies in Machiavellianism","author":"Geis","year":"1970"},{"key":"2","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/annonc\/mdq048","article-title":"Assessing oncologic benefit in clinical trials of immunotherapy agents","volume":"21","author":"Drake","year":"2010","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1634\/theoncologist.13-S2-19","article-title":"Endpoints for assessing drug activity in clinical trials","volume":"13","author":"Pazdur","year":"2008","journal-title":"The oncologist"},{"key":"4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: Multi-targeted or single-targeted?","volume":"2","author":"Peters","year":"2011","journal-title":"World J Clin Oncol"},{"issue":"Suppl 7","key":"5","first-page":"vii205","article-title":"Proteomics as a guiding tool for more effective personalized therapy","volume":"21","author":"Kohn","year":"2010","journal-title":"Ann Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1558-5646.2009.00942.x","article-title":"The animal within: carcinogenesis and the clonal evolution of cancer cells are speciation events sensu stricto","volume":"64","author":"Vincent","year":"2010","journal-title":"Evolution"},{"key":"7","first-page":"311","article-title":"Targeted therapies: a new generation of cancer treatments","volume":"77","author":"Gerber","year":"2008","journal-title":"Am Fam Physician"},{"key":"8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0167-4870(01)00067-8","article-title":"Using the Machiavellianism instrument to predict trustworthiness in a bargaining game","volume":"23","author":"Smith","year":"2002","journal-title":"Journal of Economic Psychology"},{"key":"9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fonc.2014.00293","article-title":"The war on cancer: lessons from the war on terror","volume":"4","author":"Huang","year":"2014","journal-title":"Frontiers in oncology"},{"key":"10","first-page":"387","article-title":"The war on cancer: a military perspective","volume":"4","author":"Reid","year":"2014","journal-title":"Frontiers in oncology"},{"key":"11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nrclinonc.2012.134","article-title":"Targeted therapies: the toxic reality of new drugs","volume":"9","author":"Kirk","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"12","volume-title":"A Review of disease-specific quality of life measurement scales","author":"Bouwling","year":"2001","edition":"2"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6984","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T17:49:26Z","timestamp":1589219366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,22]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,2,23]]}},"alternative-id":["6984","26814434"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.6984","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,22]]}}}